- Home
- ELEV vs VTVT Comparison
ELEV vs VTVT Comparison
Compare ELEV & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- VTVT
- Stock Information
- Founded
- ELEV 2019
- VTVT 2015
- Country
- ELEV United States
- VTVT United States
- Employees
- ELEV N/A
- VTVT N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- VTVT Health Care
- Exchange
- ELEV Nasdaq
- VTVT Nasdaq
- Market Cap
- ELEV 37.6M
- VTVT 31.9M
- IPO Year
- ELEV 2021
- VTVT 2015
- Fundamental
- Price
- ELEV $0.58
- VTVT $14.96
- Analyst Decision
- ELEV Strong Buy
- VTVT Strong Buy
- Analyst Count
- ELEV 5
- VTVT 1
- Target Price
- ELEV $7.20
- VTVT $35.00
- AVG Volume (30 Days)
- ELEV 860.8K
- VTVT 29.3K
- Earning Date
- ELEV 11-06-2024
- VTVT 11-12-2024
- Dividend Yield
- ELEV N/A
- VTVT N/A
- EPS Growth
- ELEV N/A
- VTVT N/A
- EPS
- ELEV N/A
- VTVT N/A
- Revenue
- ELEV N/A
- VTVT $1,000,000.00
- Revenue This Year
- ELEV N/A
- VTVT N/A
- Revenue Next Year
- ELEV N/A
- VTVT N/A
- P/E Ratio
- ELEV N/A
- VTVT N/A
- Revenue Growth
- ELEV N/A
- VTVT 11011.11
- 52 Week Low
- ELEV $0.44
- VTVT $7.38
- 52 Week High
- ELEV $5.83
- VTVT $30.99
- Technical
- Relative Strength Index (RSI)
- ELEV 43.94
- VTVT 46.45
- Support Level
- ELEV $0.60
- VTVT $14.52
- Resistance Level
- ELEV $0.70
- VTVT $15.54
- Average True Range (ATR)
- ELEV 0.08
- VTVT 0.98
- MACD
- ELEV -0.01
- VTVT -0.25
- Stochastic Oscillator
- ELEV 7.67
- VTVT 11.43
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.